2-chloro-5-nitro-N-(pyridin-4-yl)benzamide

• ChemBase编号: 81496
• 分子式: C12H8ClN3O3
• 平均质量: 277.66322
• 单一同位素质量: 277.02541881
• SMILES: [N+](=O)(c1cc(c(cc1)Cl)C(=O)Nc1ccncc1)[O-]
• Canonical SMILES: Clc1ccc(cc1C(=O)Nc1ccncc1)[N+](=O)[O-]
• InChI: InChI=1S/C12H8ClN3O3/c13-11-2-1-9(16(18)19)7-10(11)12(17)15-8-3-5-14-6-4-8/h1-7H,(H,14,15,17)
• InChIKey: FRPJSHKMZHWJBE-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide
• IUPAC传统名: 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide
• 别名: T0070907; 2-Chloro-5-nitro-N-4-pyridinylbenzamide; N1-(4-pyridyl)-2-chloro-5-nitrobenzamide; 2-Chloro-5-nitro-N-4-pyridinyl-benzamide; Benzamide, 2-chloro-5-nitro-N-4-pyridinyl-; T0070907; T0070907

登记号

• CAS号: 313516-66-4
• MDL号: MFCD00121849
• PubChem SID: 162068615
• PubChem CID: 2777391

理论计算性质

• Acid pKa: 10.365898
• 质子受体: 4
• 质子供体: 1
• LogD (pH = 5.5): 2.084955
• LogD (pH = 7.4): 2.384497
• Log P: 2.3914871
• 摩尔折射率: 70.5599 cm^3
• 极化性: 25.885471 Å^3
• 极化表面积: 85.13 Å^2
• 可自由旋转的化学键: 3
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: DMSO; DMSO: >10 mg/mL; H2O: insoluble
• 外观: Off-White Solid; white powder

安全信息

• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 德国WGK号: 2
• 危险公开号: 22-36
• 安全公开号: 26
• GHS危险品标识: GHS07
• GHS警示词: Warning
• GHS危险声明: H302-H319
• GHS警示性声明: P305 + P351 + P338
• 个人保护装置: dust mask type N95 (US), Eyeshields, Gloves
• 保存温度: 2-8°C

药理学性质

• 作用靶点: PPAR

产品相关信息

• 纯度: ≥98% (HPLC); 95+%; 96%
• 成盐信息: Free Base
• Empirical Formula (Hill Notation): C12H8ClN3O3

详细说明

Sigma Aldrich - T8703

Biochem/physiol Actions
T0070907 is very similar in structure and activity to the PPAR-γ antagonist GW9662. T0070907 is more potent and has higher selectivity for PPAR-γ over all other subtypes (about 800-fold) whereas GW9662 has been reported to have some PPAR-α agonist activity.

Toronto Research Chemicals - C374760

A cell-permeable chloro-nitro-benzamido compound that acts as a potent, specific, irreversible, and high-affinity antagonist of PPARγ with a Ki of 1 nM. Displays >800-fold greater selectivity for PPARγ over PPARα and PPARδ (Ki = 0.85 μM and 1.8 μM, respectively). Blocks hormone- and agonist-induced adipogenesis in 3T3-L1 cells. It suppresses interactions between PPARγ and coactivator-derived peptides, while promotes the recruitment of corepressor-derived peptides. Shown to modulate the interaction of PPARγ2 with the cofactor proteins through covalent binding to Cys313 in its ligand-binding domain.

参考文献

• Lee, G., et al: J. Biol. Chem., 277, 19649 (2003)
• Schaefer, K.L., et al: Cancer Res., 65, 2251 (2003)
• Masuda, T., et al.: Clin. Cancer Res., 11, 4012 (2003)
• Raikwar, H.P., et al.: J. Neuroimmunol., 167, 99 (2005)